

Raffaele Coppini

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4357122/raffaele-coppini-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

60
papers

1,791
citations

27
h-index

41
g-index

70
ext. papers

2,371
ext. citations

6.6
avg, IF

4.44
L-index

#	Paper	IF	Citations
60	Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. <i>Circulation</i> , 2013 , 127, 575-84	16.7	244
59	Targets for therapy in sarcomeric cardiomyopathies. <i>Cardiovascular Research</i> , 2015 , 105, 457-70	9.9	97
58	Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target. <i>International Journal of Cardiology</i> , 2017 , 243, 86-90	3.2	80
57	Action potential propagation in transverse-axial tubular system is impaired in heart failure. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 5815-9	11.5	75
56	Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2589-2600	15.1	69
55	Optogenetics design of mechanistically-based stimulation patterns for cardiac defibrillation. <i>Scientific Reports</i> , 2016 , 6, 35628	4.9	66
54	Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. <i>European Journal of Heart Failure</i> , 2016 , 18, 1106-18	12.3	64
53	Mechanisms of pro-arrhythmic abnormalities in ventricular repolarisation and anti-arrhythmic therapies in human hypertrophic cardiomyopathy. <i>Journal of Molecular and Cellular Cardiology</i> , 2016 , 96, 72-81	5.8	63
52	Defects in T-tubular electrical activity underlie local alterations of calcium release in heart failure. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 15196-201	11.5	63
51	Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy: The RESTYLE-HCM Randomized, Double-Blind, Placebo-Controlled Study. <i>Circulation: Heart Failure</i> , 2018 , 11, e004124	7.6	56
50	Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	55
49	Content of mitochondrial calcium uniporter (MCU) in cardiomyocytes is regulated by microRNA-1 in physiologic and pathologic hypertrophy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, E9006-E9015	11.5	55
48	Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction. <i>British Journal of Pharmacology</i> , 2017 , 174, 3696-3712	8.6	48
47	UDP-glucose enhances outward K(+) currents necessary for cell differentiation and stimulates cell migration by activating the GPR17 receptor in oligodendrocyte precursors. <i>Glia</i> , 2013 , 61, 1155-71	9	45
46	Liquid Crystalline Networks toward Regenerative Medicine and Tissue Repair. <i>Small</i> , 2017 , 13, 1702677	11	36
45	Impact of detubulation on force and kinetics of cardiac muscle contraction. <i>Journal of General Physiology</i> , 2014 , 143, 783-97	3.4	36
44	Chronic atrial fibrillation alters the functional properties of If in the human atrium. <i>Journal of Cardiovascular Electrophysiology</i> , 2013 , 24, 1391-400	2.7	34

43	Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience. <i>European Journal of Heart Failure</i> , 2018 , 20, 898-906	12.3	34
42	Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center. <i>Genetics in Medicine</i> , 2019 , 21, 284-292	8.1	32
41	Pathogenesis of Hypertrophic Cardiomyopathy is Mutation Rather Than Disease Specific: A Comparison of the Cardiac Troponin T E163R and R92Q Mouse Models. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	32
40	Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium. <i>Pharmacological Research</i> , 2020 , 157, 104781	10.2	31
39	Late sodium current inhibitors to treat exercise-induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium. <i>British Journal of Pharmacology</i> , 2018 , 175, 2635-2652	8.6	31
38	Development of Light-Responsive Liquid Crystalline Elastomers to Assist Cardiac Contraction. <i>Circulation Research</i> , 2019 , 124, e44-e54	15.7	30
37	Novel Approach Targeting the Complex Pathophysiology of Hypertrophic Cardiomyopathy: The Impact of Late Sodium Current Inhibition on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy (LIBERTY-HCM) Trial. <i>Circulation: Heart Failure</i> , 2016 , 9, e002764	7.6	30
36	Altered Ca and Na Homeostasis in Human Hypertrophic Cardiomyopathy: Implications for Arrhythmogenesis. <i>Frontiers in Physiology</i> , 2018 , 9, 1391	4.6	30
35	Clinical research in neonates and infants: Challenges and perspectives. <i>Pharmacological Research</i> , 2016 , 108, 80-87	10.2	29
34	Oleuropein Aglycone Protects against MAO-A-Induced Autophagy Impairment and Cardiomyocyte Death through Activation of TFEB. <i>Oxidative Medicine and Cellular Longevity</i> , 2018 , 2018, 8067592	6.7	28
33	Selective Blockade of HCN1/HCN2 Channels as a Potential Pharmacological Strategy Against Pain. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1252	5.6	26
32	Isolation and functional characterization of human ventricular cardiomyocytes from fresh surgical samples. <i>Journal of Visualized Experiments</i> , 2014 ,	1.6	22
31	Abnormalities in sodium current and calcium homeostasis as drivers of arrhythmogenesis in hypertrophic cardiomyopathy. <i>Cardiovascular Research</i> , 2020 , 116, 1585-1599	9.9	16
30	Impact of Genotype on the Occurrence of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2016 , 117, 1151-9	3	16
29	R4496C RyR2 mutation impairs atrial and ventricular contractility. <i>Journal of General Physiology</i> , 2016 , 147, 39-52	3.4	16
28	Optical Investigation of Action Potential and Calcium Handling Maturation of hiPSC-Cardiomyocytes on Biomimetic Substrates. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	15
27	Altered calcium regulation in isolated cardiomyocytes from Egr-1 knock-out mice. <i>Canadian Journal of Physiology and Pharmacology</i> , 2013 , 91, 1135-42	2.4	15
26	A Novel Method of Isolating Myofibrils From Primary Cardiomyocyte Culture Suitable for Myofibril Mechanical Study. <i>Frontiers in Cardiovascular Medicine</i> , 2019 , 6, 12	5.4	14

25	Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy: A Translational Study. <i>JACC Basic To Translational Science</i> , 2019 , 4, 795-813	8.7	13
24	Regulation of intracellular Na(+) in health and disease: pathophysiological mechanisms and implications for treatment. <i>Global Cardiology Science & Practice</i> , 2013 , 2013, 222-42	0.7	13
23	Dexpropipexole blocks Nav1.8 sodium channels and provides analgesia in multiple nociceptive and neuropathic pain models. <i>Pain</i> , 2020 , 161, 831-841	8	13
22	Histopathological comparison of intramural coronary artery remodeling and myocardial fibrosis in obstructive versus end-stage hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2019 , 291, 77-82	3.2	12
21	Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 2413-2422	8.8	12
20	Understanding the heart-brain axis response in COVID-19 patients: A suggestive perspective for therapeutic development. <i>Pharmacological Research</i> , 2021 , 168, 105581	10.2	12
19	T-Tubular Electrical Defects Contribute to Blunted β Adrenergic Response in Heart Failure. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	10
18	Electrical defects of the transverse-axial tubular system in cardiac diseases. <i>Journal of Physiology</i> , 2017 , 595, 3815-3822	3.9	9
17	Functional cardiac imaging by random access microscopy. <i>Frontiers in Physiology</i> , 2014 , 5, 403	4.6	8
16	Mavacamten has a differential impact on force generation in myofibrils from rabbit psoas and human cardiac muscle. <i>Journal of General Physiology</i> , 2021 , 153,	3.4	8
15	Response to letter regarding article, "Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy". <i>Circulation</i> , 2013 , 128, e157	16.7	7
14	Representativeness of the "Fiesole Misurata" study database for use in pharmaco-epidemiological investigations on adherence to antihypertensive medications. <i>Aging Clinical and Experimental Research</i> , 2013 , 25, 433-45	4.8	6
13	Sex-Specific Classification of Drug-Induced Torsade de Pointes Susceptibility Using Cardiac Simulations and Machine Learning. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 380-391	6.1	6
12	Advances in Stem Cell Modeling of Dystrophin-Associated Disease: Implications for the Wider World of Dilated Cardiomyopathy. <i>Frontiers in Physiology</i> , 2020 , 11, 368	4.6	4
11	Channelopathies, cardiac hypertrophy, and the theory of light. <i>European Heart Journal</i> , 2018 , 39, 2908-2910	3.9	4
10	Pharmacological Inhibition of Serine Proteases to Reduce Cardiac Inflammation and Fibrosis in Atrial Fibrillation. <i>Frontiers in Pharmacology</i> , 2019 , 10, 1420	5.6	4
9	Clinical and Molecular Aspects of Cardiomyopathies: Emerging Therapies and Clinical Trials. <i>Heart Failure Clinics</i> , 2018 , 14, 161-178	3.3	3
8	Anti-hypertensive drugs deprescribing: an updated systematic review of clinical trials. <i>BMC Family Practice</i> , 2021 , 22, 208	2.6	2

7	Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives. <i>Current Heart Failure Reports</i> , 2021 , 18, 169-179	2.8	2
6	Modelling genetic diseases for drug development: Hypertrophic cardiomyopathy. <i>Pharmacological Research</i> , 2020 , 160, 105176	10.2	1
5	T-tubule remodeling in human hypertrophic cardiomyopathy. <i>Journal of Muscle Research and Cell Motility</i> , 2021 , 42, 305-322	3.5	1
4	Genotype-Driven Pathogenesis of Atrial Fibrillation in Hypertrophic Cardiomyopathy: The Case of Different Mutations.. <i>Frontiers in Physiology</i> , 2022 , 13, 864547	4.6	0
3	Neural Effects on Cardiac Electrophysiology 2020 , 973-985		
2	Neural Effects on Cardiac Electrophysiology 2019 , 1-13		
1	Novel pharmacological approaches for paediatric hypertrophic cardiomyopathy. <i>Progress in Pediatric Cardiology</i> , 2018 , 51, 46-54	0.4	